Genomics of response to immune checkpoint therapies for cancer: Implications for precision medicine

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

14 p | 3 | 2

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

15 p | 3 | 2

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: Insights from genomic sequencing

6 p | 2 | 2

Large-scale public data reuse to model immunotherapy response and resistance

8 p | 2 | 2

The good, the bad, and the ugly: Hyperprogression in cancer patients following immune checkpoint therapy

3 p | 2 | 2

Longitudinal analysis of treatment-induced genomic alterations in gliomas

10 p | 1 | 1

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

16 p | 1 | 1

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach

3 p | 1 | 1

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

23 p | 6 | 0